1. Accelerating progress from advanced to early breast cancer (SERDS, PI3Kinhibitors, other novel agents). (April 2021) Authors: Cescon, D. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237. (October 2022) Authors: Rushton, M.; Cescon, D.; Hilton, J.; Bedard, P.; Blanchette, P.; Bashir, A.; Pezo, R.; Kumar, V.; Ng, T.; Awan, A.; Lott, A.; Raphael, J.A.; Hagerman, L.; Bray, M.; Muyot, L.; Fuentes Antras, J.; Seymour, L.; Tu, D.; Gaudreau, P.O. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗